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ACLF is a specific, but complex and multifactorial form of acute decompensation of cirrhosis and is characterized by an
extraordinary dynamic natural course, rapidly evolving organ failure, and high short-term mortality. Dysbalanced immune
function is central to its pathogenesis and outcome with an initial excessive systemic inflammatory response that drives organ
failure and mortality. Later in its course, immuno-exhaustion/immunoparalysis prevails predisposing the patient to secondary
infectious events and reescalation in end-organ dysfunction and mortality. The management of patients with ACLF is still poorly
defined. However, as its pathophysiology is gradually being unravelled, potential therapeutic targets emerge that warrant further
study such as restoring or substituting albumin via plasma exchange or via albumin dialysis and evaluating usefulness of TLR4
antagonists, modulators of gut dysbiosis (pre- or probiotics), and FXR-agonists.
1. Acute-on-Chronic Liver Failure and
Systemic Inflammation
Acute clinical deterioration of a patient with cirrhosis
remains a decisive time point in terms of medical manage-
ment, since it is frequently associated with rapidly evolv-
ing multiorgan dysfunction, significant morbidity, and high
short-term mortality. In the latter clinical constellation, this
syndrome has been referred to as acute-on-chronic liver
failure (ACLF) [1, 2]. The CANONIC study, the largest
prospective multicenter study on ACLF so far with inclusion
of 1343 patients admitted with acute decompensation of
cirrhosis, has substantiated its relevance and clinical impact
by documenting a prevalence of ACLF in this cohort of 30.9%
accompanied by a high short-term mortality of 33 and 51%
at 28 and 90 days, respectively (Table 1) [2]. In addition,
the CANONIC study [2] and subsequent analyses [3] have
exposed several premises with regard to the pathophysiology
of ACLF and in particular a pivotal role for dysregulated
inflammation. More specifically, the degree of inflammatory
response, as estimated by the leukocyte count and C-reactive
protein, was found to be an independent predictor of post-
enrolment development of ACLF and paralleled the severity
and outcome of ACLF (Figure 1). All patients with ACLF
showed a high leukocyte count and C-reactive protein which
in 60% of patients could be attributed to an inflammatory
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Figure 1: Proof of dysbalanced inflammatory response: relationship between the degree of inflammatory reaction, as estimated by the
leukocyte count and C-reactive protein, and the severity of ACLF.
Table 1: Definition and prognosis of ACLF.
Grade of ACLF 28-daymortality
90-day
mortality
ACLF grade 1
(i) Single kidney failure
22.1% 40.7%(ii) Single “non-kidney” organ
failure with serum creatinine
ranging from 1.5 mg/dl to 1.9 mg/dl
and/or grade I or II hepatic
encephalopathy
ACLF grade 2: Presence of 2 organ
failures 32% 52.3%
ACLF grade 3: Presence ≥3 organ
failures 76.7% 79.1%
Minimal organ failures defined by the modified Sequential Organ Failure
Assessment (SOFA) score for patients with cirrhosis:
(i) Liver: bilirubin ≥ 12mg%
(ii) Kidney: creatinine ≥ 2.0mg%
(iii) Cerebral: hepatic encephalopathy ≥ grade 3
(iv) Coagulation: INR ≥ 2.5 or platelets < 20.000 per mm3
(v) Circulation: need of vasopressors
(vi) Lungs: PaO/FiO2 > 100
trigger such as bacterial infection or acute alcoholic liver
injury whereas in the remaining 40% this remains undeter-
mined at present. Together these findings suggest an altered
host response to injury, both infectious and noninfectious,
and immune dysfunction leading to an inappropriate inflam-
matory response. On the other hand, the CANONIC-trial
also taught us that ACLF patients, who had earlier episodes
of acute hepatic decompensation, developed a less dramatic
course of ACLF with lower levels of inflammatory mediators
and lower mortality rates compared to patients presenting
with a first episode. This suggests that ACLF is not only
associated with exaggerated inflammatory response but also
with tolerance, a host defence strategy that reduces the
negative impact of inflicted injury on host fitness [4].
In the next paragraphs, we will focus first on the basic
mechanisms of inflammation (resistance and tolerance),
secondly on the different elements contributing to this
dysfunction and predominantly in the context of ACLF
in patients with underlying cirrhosis (cirrhosis-associated
immune dysfunction), and thirdly on additional reinforcing
accomplices.
2. Systemic Inflammation:
Resistance and Tolerance
If we focus on the healthy liver, it is to be considered as a
frontline immunological organ as it balances between “resis-
tance” and “tolerance” [5]. It acts as a gatekeeper via its unique
double blood supply, the arterial blood of the hepatic artery,
and the portal-venous blood delivering the products resorbed
in the intestine. On the one hand, the liver maintains
immune surveillance. To accomplish this role, the liver con-
tains numerous resident antigen presenting cells strategically
located to allow maximal “border control”. These involve the
reticuloendothelial system (endothelial cells, Kupffer cells)
and dendritic cells, which following detection participate in
coordinated immune responses leading to pathogen clear-
ance, leukocyte recruitment, and antigen presentation to lym-
phocytes within the unique hepatic vasculature. In addition
to this local surveillance role, the liver is responsible for the
bulk production of proteins involved in innate and adaptive
immune responses following stimulation by proinflamma-
tory cytokines (such as interleukin- [IL-] 6, tumor necrosis
factor- [TNF-] alpha), including acute phase proteins such
as C-reactive protein and lipopolysaccharide binding protein,
and complement factors. Conversely, its defensive reactive
role is being tightly regulated by, amongst others, high IL-10
production by Kupffer cells and Kupffer cell mediated T-cell
suppression to ensure that inappropriate immune responses
are not raised against nonpathogenic exogenous blood-borne
molecules, such as those derived from food and conventional
gut microbial antigens [5].
When a threat arises to our physical integrity, it is pri-
marily dealt by “resistance” mechanisms. This refers to the
attempts of the host immune system to “search and destroy”.
Crucial in the initial resistance phase of an infectious threat
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Table 2: Examples of well-characterized DAMPs (danger signals or alarmins).
DAMPs Receptors Outcome of receptor ligation
Extracellular nucleotides
(ATP, ADP, adenosine)
PI, P2X, and P2Y receptors
(ATP, ADP); Al, A2A, A2B,
and A3 receptors
(adenosine)
Dendritic cell (DC) maturation, chemotaxis, secretion
of cytokines (IL-1𝛽, IL-18), inflammation
Extracellular heat shock
proteins
CD14, CD91, scavenger
receptors, TLR4, TLR2,
CD40
DC maturation, cytokine induction, DC, migration to
lymph nodes
Extracellular HMGB1 RAGE, TLR2, TLR4
Chemotaxis, cytokine induction, DC activation,
neutrophil recruitment, inflammation, activation of
immune cells
Uric acid crystals CD14, TLR2, TLR4 DC activation, cytokine induction, neutrophilrecruitment, gout induction
Laminin Integrins Neutrophil recruitment, chemotaxis
S100 proteins or
calgranulins RAGE
Neutrophil recruitment, chemotaxis, cytokine
secretion, apoptosis
Hyaluronan TLR2, TLR4, CD44 DC maturation, cytokine production, adjuvant activity
IL-1 family
IL-1𝛼 IL1R1 and IL1RAP
Inflammatory; promotes activation, costimulation, and
secretion of cytokines and other acute-phase proteins;
pyrogenic
IL-33 IL1RL1 and IL1RAP
Inducer of type 2 immune responses, activating T
helper 2 (TH2) cells and mast cells; stimulates group 2
innate lymphoid cells (ILC2s), regulatory T (Treg) cells,
TH1 cells, CD8+ T cells and natural killer (NK) cells.
Mitochondrial DAMPs
mtDNA TLR9
Proinflammatory cytokines, neutrophil
chemoattraction and matrix metalloproteinase
secretion, type I IFN responses 91
N-Formylated peptides FPR Neutrophil chemoattraction
are toll-like receptors (TLRs), which recognize distinct con-
served structures in pathogens (pathogen-associated molec-
ular patterns, PAMPs) and lead to sensing pathogen invasion,
triggering innate immune responses, and priming antigen-
specific adaptive immunity [6, 7]. The intracellular cascades
triggered by TLR-activation lead to transcription factor acti-
vation (e.g., nuclear factorNF-𝜅𝛽, AP-1) and subsequent tran-
scriptional activation of hundreds of inflammatory mediator
genes coding, for instance, for cytokines (i.e., TNF-𝛼, IL-6,
IL-1𝛽, or type 1 interferons), which further shape the immune
response and the elimination of bacteria and infected cells.
Safeguarding the host from invading pathogens is an intricate
task that requires cooperation between different pattern
recognition receptors (PRRs). While responses to extracellu-
lar PAMPs are mainly mediated by membrane bound recep-
tors such as TLRs, other cytosolic receptors (the nucleotide-
binding oligomerization domain- (NOD-) like receptor,
NLRs) are specialized for detection of PAMPs that reach the
cytosol or intracellular organelles [7]. Several members of the
NLR gene family are involved in the assembly ofmacromolec-
ular protein complexes termed “inflammasomes” that lead to
the activation of the inflammatory cysteine protease, caspase-
1 (also known as interleukin-1 converting enzyme or ICE).
Caspase-1 in turn cleaves pro-IL-1𝛽 or pro-IL-18, resulting in
secretion of the mature and active forms of these cytokines
[8].
In noninfectious threats due to acute tissue necrosis or
immune-inflicted damage (such as fulminant hepatitis or
acute alcoholic hepatitis), necrotic cells release damage/
danger-associated molecular patterns (DAMPs), consisting
of denaturated nuclear or cytosolic proteins, nucleic acids,
and so forth, which also interact with TLRs and other
specific receptors [9] (Table 2). Therefore, the host response
to infectious and noninfectious (“sterile”) injury is not sub-
stantially different. DAMPs also activate inflammasomes that
process the release of IL-1𝛽, which initiates the activation of
cytokines, as mentioned earlier [8, 9]. However, differences
in host (genetic variants in genes coding for cytokines and
other regulatory factors of the innate and adaptive immune
systems) and pathogen (virulence, load) factors may lead to
variable intensity of immune responses and susceptibility to
certain pathogens. Either way, the trade-off for an exagger-
ated “search and destroy” strategy is collateral damage lead-
ing to “immunopathology”, defined as the negative impact of
immune defence on host fitness.
To deal with this endogenous endangered physical
integrity, a 2nd mechanism is activated called “disease
tolerance” [4]. This refers to a distinct defence strategy that
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decreases host susceptibility to tissue damage caused by a
pathogen or local factor or by the immune response directed
against them (immunopathology). Whereas direct damage
caused by pathogens relates to their burden and virulence
and an incompetent immune response, immunopathology
correlates positively with the magnitude and duration of the
immune response. Therefore an optimal immune response
balances between an efficient pathogen clearance and accept-
able level of immunopathology.
Although much of the knowledge regarding the mecha-
nisms involved in tolerance remains to be elucidated, logically
these would be expected to prevent, reduce, or counter
inflicted damage and thus involve engagement of basal and
inducible homeostatic systems (amongst others by induc-
tion of stress-response genes to tone down hypersensitivity)
restoring/reducing fitness costs following infectious aggres-
sion. An example of such a counterbalancing reaction is the
activation of compensatory anti-inflammatory mechanisms
in order to restrain a potential overzealous proinflammatory
process in patients with infectious or noninfectious systemic
inflammatory response. These mechanisms concert with
an adapted compartmentalized response with the aim of
silencing some acute proinflammatory genes and tomaintain
the possible expression of certain genes involved in the anti-
infectious process (and by combination thus to reduce the
burden of immunopathology) [10, 11]. Enhanced release of
anti-inflammatory mediators such as IL-10, IL-1 receptor
antagonist (IL-1RN), and soluble TNF-𝛼 receptor, as well as
decreased HLA-DR expression (altering antigen presentation
capacity) on different antigen presenting cells amongst oth-
ers, dampens the inflammatory component. In contrast to
what was initially postulated, the anti-inflammatory response
is no longer considered a generalized damping phenomenon
sequentially following a systemic inflammatory response but
rather a concomitant compartmentalized reprogramming
of leukocytes leading to an oscillating balance (immune
dissonance) between the two opposed forces driving outcome
[11, 12].This particular premise is substantiated by the finding
that repeated exposure of in vitro murine macrophages to
bacterial endotoxin/ lipopolysaccharides (LPS) led to tran-
sient silencing of proinflammatory genes (e.g., TNF-𝛼, IL-6,
IL-1ß, IL-12, and type 1 IFN), priming of anti-inflammatory
(e.g., IL-10, transforming growth factor- (TGF-) 𝛽, and IL-
1RN) and antimicrobial effector genes, and impairing antigen
presenting capacity (via decreased expression of HLA-DR),
leading to a phenomenon called “endotoxin tolerance” [12–
14]. These adaptive changes are also commonly associated
phenotype switch (M1 󳨀→M2) and altered substrate uti-
lization. These findings illustrate an adaptive response in
macrophages and reveal component-specific regulation of
inflammation adding up to the complexity of the balancing
act between resistance and tolerance.
3. Resistance and Tolerance in
ACLF: Cirrhosis-Associated Immune
Dysfunction (Figure 2)
In a cirrhotic patient, immune function becomes an even
more complex and often confusing matter as it can take
a rapidly interchangeable and highly fluctuating course of
either “too much, or not enough” resistance/inflammation
[1–3, 10, 15, 16]. Recently, this immune dysfunction syn-
drome in the context of cirrhosis has been referred to as
cirrhosis-associated immune dysfunction [17]. It consists
of two concomitant, interlinked, and seemingly opposed
forces: systemic inflammation and acquired immunodefi-
ciency. These reciprocally and dynamically drive immune-
(in)competence during the course of cirrhosis. This fragile
balancing act is already activated in the early stages of
cirrhosis (compensated state) as the cause that drives the
cirrhogenesis process primes a proinflammatory phenotype
by the activation of DAMPs from injury-inflicted tissue
damage which is proportional to the etiological force driving
chronic liver disease (such as alcohol, HBV, and HCV).
As cirrhosis progresses and thus hepatocellular injury and
intrahepatic shunting via completely vascularized fibrotic
septae increase, the “gate-keeper function” of the liver is
hollowed out. More specifically, hepatocellular insufficiency
leads to the decreased production of PRRs, acute phase
proteins, albumin, complement, and so forth and therefore
progressive loss of opsonization, bacterial phagocytosis, and
killing, while increased shunting leads to evasion of portal
and systemic bacteria to the action of the reticuloendothe-
lial system. Both features explain why bacterial products
such as endotoxins and cytokines are insufficiently cleared
and further prime systemic inflammation. As the severity
of cirrhosis increases, bacterial translocation from the gut
(see below) amplifies. This is paralleled by increased levels
of PAMPs (and subsequent TLR/NLRs activation), which
instigate the activation of the hepatic innate immune system,
reinforcing further hepatic injury directly and indirectly
through immunopathology. Initially, the spill-over of PAMPs
furthers amplifies, and sometimes infuriates, the already
primed proinflammatory systemic response as witnessed in
LPS-stimulated cirrhotic peripheral blood mononuclear cells
(PBMCs) which showed a massive induction of proinflam-
matory cytokines and chemokines [13, 14, 17–23].
Later on, as circulating and intestinal populations of
immune cells are more and more compromised with evolv-
ing liver damage and mechanisms like “endotoxin toler-
ance” (with priming of anti-inflammatory (e.g., IL-10, TGF-𝛽,
and IL-1RA) and impairing antigen presenting capacity (via
decreased expression of HLA-DR), see earlier) become gen-
eralized, the dynamic balance switches over to a predominant
immunodeficient phenotype [17–19]. One of the recently
elucidated pathways in this latter context is the finding
of Bernsmeier et al. [24] who showed that patients with
ACLF in comparison to patients with compensated and
mere acute decompensation of cirrhosis had increased num-
bers of MER receptor tyrosine kinase (MERTK) expressing
monocytes and macrophages. MERTK negatively controls
innate immune response. In ACLF, MERTK expression
correlated with the severity of hepatic and extrahepatic
disease and systemic inflammatory response. Moreover, in
vitro MERTK-inhibitors were able to restore the produc-
tion of inflammatory cytokines in response to lipopolysac-
charide stimulation. Additional work in this context fur-
ther highlighted the important role of immunosuppressive
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Figure 2: The dynamic course of immune function in evolving cirrhosis: cirrhosis-associated immune: (a) early cirrhosis sets the stage for
ACLF; (b) evolving cirrhosis primes the systemic immune system and finally culminates in ACLF (c).
mononuclear CD14+HLA-DR− myeloid-derived suppressor
cells (M-MDSCs) who equally quell on antimicrobial defen-
ces in ACLF [25].
However, immune activation and deficiency can coexist.
Intestinal macrophages in cirrhosis are activated due to
bacterial translocation (compartmentalized immune activa-
tion while at the same time immune responses may fail
systemically) [20].
While endotoxin tolerance, and an anti-inflammatory
response in general, is conceived as a primarily protec-
tive mechanism, its protracted duration and outbalanced
intensity have been associated with high risks of secondary
infections and death [11, 12, 18, 19].
The clinical implications of this skewed homeostatic bal-
ance between resistance and tolerance in cirrhosis translate
in essence in the end-organ failure that determines ACLF.
Although tolerance capacity differs depending on organ
(given the difference in intrinsic damage susceptibility, repair
capacity, functional autonomy, and damage or malfunction
sequelae), dysbalanced inflammation may eventually cause
organ failure through different mechanisms. First, through
the action of circulating proinflammatory mediators and
membrane-shed microparticles, it causes an escalation of
the portal hypertensive syndrome leading to an aggravated
systemic circulatory dysfunction characterized by arterial
vasodilation, impairment in cardiac function, organ hypop-
erfusion, and end-organ ischemia [26–30]. Second, the direct
extension of systemic inflammation to organs impairs cell
function and may cause necrosis and/or apoptosis. In lung
and kidney, detection of TLR4 forms the direct link between
increasing circulating microbial products and the subsequent
proinflammatory cascade in this end-organ injury [31, 32].
A recent paper by Cla`ria et al. [3] has documented high
circulating levels of pro- and anti-inflammatory cytokines in
ACLF, whose levels significantly correlated with the number
of organ failures. Moreover, different profiles of cytokine
response were identified depending on the type of precip-
itating event (like, for example, alcoholic steatohepatitis or
bacterial infection).
This same study revealed that not only inflammatory
markers, but alsomarkers of oxidative stress (e.g., oxidized al-
bumin, see below) known to drive systemic inflammation,
might help to identify patients with ACLF and predict
their outcome. Other clinical observations underscoring
the impact of this dysbalance are, for example, the obser-
vation that in patients with increasing grade of ACLF and
HRS the response to terlipressin and albumin is blunted
[33]. Additionally, the exaggerated anti-inflammatory
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response/immune-tolerance may facilitate the appearance of
bacterial infections. Indeed, in the CANONIC study cohort,
46% of patients with ACLF without bacterial infections at
diagnosis of ACLF developed a bacterial infection within 4
weeks, with devastating impact on short term mortality [34].
Finally, inflammation increases the release of local pro-
coagulant factors (including tissue factor and membrane mi-
croparticles) from the endothelial cells, inducing micro-
thrombosis in the microcirculation of different organs [35].
In conclusion, in addition to impaired circulatory func-
tion, systemic inflammation may lead to organ failure by a
direct effect of the inflammatory mediators on microvascular
integrity, cell function, and death mechanisms. As such the
peripheral vasodilation theory no longer exclusively explains
the mechanism of organ failure but embraces the systemic
inflammation hypothesis in evolving cirrhosis [36].
4. Other Partners in Crime
In addition to inflammation, the following factors are thought
to contribute as “accomplices” in the hold-up ACLF imposes
on a patient.
4.1. Inflammaging and Immunosenescence. Patients with
ACLF in the CANONIC study were of younger age under-
lining that the younger patients have the stronger response
and thereby are more susceptible to develop ACLF [2]. In
subsequent publications using different independent cohorts
for the elaboration of the CLIF-C-AD score, a measure to
calculate the risk of ACLF and death, younger age seems to
be associated with ACLF development [37]. Previously, such
trends did not reach statistical significance, but were also
described [38, 39]. However, looking on the other side, TLR
expression and function declines with age, thereby leading
to an inadequate response to infections [40]. But on the
other side, rate and severity of infections are higher and the
outcome is poorer in older patients [41].
The concepts of immunosenescence and inflammaging
might render these thoughts even more complex [42, 43].
Immunosenescence, characterized by impaired adaptive and
innate immune systems (from decrease in na¨ıve T-cells,
increase in memory cells, skewing of myeloids, impaired
chemotaxis, and effector functions in neutrophils to defects in
NK-cells and monocyte dysregulation [44]), leads also to
unsustained memory response to new antigens and might
increase the rate of autoimmune responses, as well as inflam-
maging [45]. Inflammaging is a lingering, low-grade chronic
inflammation. This proinflammatory environment is mainly
due to the senescence-associated secretory phenotype (SASP)
of the senescent immune cells [42, 43], resembling on the one
side the processes during chronic liver injury and fibrogenesis
[45] and on the other side the processes in mitochondria
and autophagy-inflammation-cell death axis, which are quite
similar to those described for alcoholic hepatitis and NASH
[46–49].
Interestingly, chronic latent viral infections such as CMV
and HCV might promote immunosenescence [50, 51] and
thereby predispose even younger patients to ACLF. Most
importantly the immunological ageing is additionally shaped
by infections, and those might tailor the inflammatory
response to specific insults [45, 52–54]. Chronic latent viral
infections, especially CMV, but also HCV and HIV, might
promote chronic systemic inflammation and increased levels
of proinflammatory cytokines (IL-6, TNF-𝛼), associated with
premature death [51, 52, 55–57].The low-grade inflammation
after latent viral infections also induces premature ageing,
predisposing cirrhotic patients to ACLF. This is supported
by the fact that reactivation of HBV is a major precipitating
factor for the development of ACLF, especially in Asia [39,
58, 59]. Hepatitis E might also be an important trigger for the
development of ACLF, whose role is still in discussion [39].
Moreover, inflammaging is associated with impaired
production of estrogen and androgen, an impairment that is
also present in cirrhosis [60, 61]. Therefore, besides age, the
latent infections,mitochondria damage, and decreased sexual
hormones might lead to premature immunosenescence and
inflammaging in chronic liver disease and predisposing for
ACLF development.
4.2. Albumin and Prostaglandin E2 (PGE2). Albumin, the
most abundant extracellular protein in our system and
synthetized exclusively by the liver, is pivotal in maintaining
colloid osmotic pressure (for about 70%) but is also endowed
with other vital non-oncotic properties, such as antioxidant
and scavenging activity (via its sulfhydryl-groups), binding
of highly toxic reactive metal species (Cu, Ni, Co, and Fe),
and transport of endogenous (such as bilirubin, endotoxin,
long-chain fatty acids) and exogenous toxins via the amino-
terminal NH2 [62]. Albumin has been found to be a predictor
of survival both in compensated and decompensated cirrho-
sis and ACLF [63, 64]. Studies have shown that in patients
with cirrhosis albumin is subjected to posttranscriptional
modifications leading to oxidized forms of albumin with
impairment of its non-oncotic biological properties and thus
leading to decreased “effective” albumin concentration [60].
Emerging recent evidence links this decreased “effective”
(no longer native and reduced) albumin in decompensated
cirrhosis to increased circulating PGE
2
-bioavailability [65].
PGE
2
, a cyclooxygenase-derived lipid mediator, is known to
play a dual role in immunity since it is a major medi-
ator of inflammation and fever, but a potent inducer of
immune suppression by depressing the effector functions
of macrophages and neutrophils [66]. Increased free PGE
2
levels, due to decreased effective binding capacity of albu-
min, might therefore explain the profound immunodefi-
ciency and associated bacterial infections typical of acutely
decompensated cirrhosis. Turning this paradigm around, the
authors showed that treatment of five patients with acutely
decompensated cirrhosis with 200 ml of 20% HSA increased
serum albumin concentrations from 23 g/l to 30 g/l and
reversed immunosuppression [65]. In an extended and larger
sample size feasibility study of 20% HSA infusions, the same
group has meanwhile confirmed that infusions to raise serum
albumin above 30 g/L reversed plasma-mediated immune
dysfunction [67]. However, in this study the reversal of
immune dysfunction following HAS therapy appeared to
be mediated by changes in the circulating levels of a novel
series of anti-inflammatory and proresolving lipid mediators
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generated from long-chain omega-3 polyunsaturated fatty
acids rather than by binding of PGE
2
[67].
Attempts to substitute or cleanse albumin (via albumin
dialysis or plasma exchange) might therefore prove interest
and warrant further investigation. In favour of this premise
is the recently presented ANSWER study [68]. This ran-
domised, controlled trial of 440 patients with cirrhosis and
uncomplicated ascites compared standard diuretic therapy
with standard diuretic therapy plus human albumin (40 g
intravenously twice weekly in the first two weeks and then
once weekly). Treatment with human albumin reduced the
risk of death by 38%. In addition, albumin infusions also
rendered significant benefits with regard to management
of ascites, complications of cirrhosis (spontaneous bacterial
peritonitis (SBP), non-SBP bacterial infection, renal dysfunc-
tion, hepatorenal syndrome, and hepatic encephalopathy),
quality of life, and hospital admissions.
4.3. Farnesoid X-Receptor (FXR). FXR is a ligand-activated
transcription factor belonging to the nuclear receptor super-
family and acts as sensor for a broad range of natural
ligands with bile acids as the most potent ones, in particular
chenodeoxycholic acid.Therefore, FXR is highly expressed in
bile acid-handling tissues such as liver, intestine, and kidney.
Upon binding of bile acids to FXR, the receptor translocates
to the nucleus where it forms a heterodimer with its binding
partner retinoid-X receptor (RXR) and through its DNA-
binding domain directly influences the transcription of a
large variety of target genes [65, 66]. Since FXR is at the cross-
road ofmetabolic regulation, inflammation, and regeneration
in normal tissue, it is driving key regulator functions.
Recent translational research has suggested a central
role for defective farnesoid-X-receptor signaling in hepatic
inflammation, portal hypertension, and intestinal bacterial
translocation, factors which are known to promote and shape
ACLF and are potentially targetable through pharmacologi-
cal agonists [69–74].
4.4. Gut Microbiota. Intestinal dysbiosis is characterized
by imbalanced quantitative and qualitative changes in the
composition of the gut microbiota and is associated with
alterations of metabolic activity as well as an altered distribu-
tion of its microbial members. In recent years, accumulating
evidence has indicated that microbial products trigger and
instigate liver inflammation and that progressive qualitative
changes in the gut microbiome (autochthonous to non-
autochthonous taxa abundance) accompany cirrhosis and
becomemore severe in the setting of decompensation [75]. In
a recent case-control study in patients with ACLF of diverse
etiology, the severity of gut dysbiosis was found worse in
ACLF than in cirrhosis (considered as “a press disturbance”
implying long-term impact on an ecosystem) with only
moderate impact of antibiotics on its composition [76].
Additionally, the authors found that the specific gut dysbiosis
in ACLF was associated with outcome, with abundance of
Pasteurellaceae as independent predictor of mortality. More
specifically, network-analysis comparison showed robust
correlations between specific bacterial families (Ruminococ-
caceae and Lachnospiraceae) and inflammatory cytokines
(IL-6, TNF-𝛼, IL-2) in ACLF patients, indicating that gut
microbiota constitutes a major backbone in ACLF pathogen-
esis and perpetuation [48].
5. Conclusions
ACLF is a specific, but complex and multifactorial form of
acute decompensation of cirrhosis and is characterized by
an extraordinary dynamic natural course, rapidly evolving
organ failure, and high short-term mortality. Dysbalanced
inflammation is central to its pathogenesis and outcome
with an initial excessive systemic inflammatory response
associated that drives organ failure and mortality. Later
in its course, immuno-exhaustion/immunoparalysis prevails
predisposing the patient to secondary infectious events and
reescalation in end-organ dysfunction and mortality.
Further studies are needed to evaluate and characterize
the evolving course of systemic inflammation starting from
compensated cirrhosis over mere acute decompensation to
ACLF. In addition, specific systemic inflammation signatures
and organdysfunction/failure are to be assessed as are specific
inflammatory prophiles per triggering event. These studies
hopefully will be able to guide future management, in terms
of both prevention and treatment and/or organ specific
approaches, for patients with AD and ACLF. For now, as
its pathophysiology is gradually being unravelled, potential
therapeutic targets emerge that warrant further study such
as restoring or substituting albumin via plasma exchange
or via albumin dialysis and evaluating usefulness of TLR4
antagonists, modulators of gut dysbiosis (pre- or probiotics),
and FXR-agonists.
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